Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial

OBJECTIVES: To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP). METHODS: In this randomized, double-blind trial, patients received tafamidis 20 mg QD or placebo. Coprimary endpoints were th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Coelho, Teresa, Maia, Luis F., Martins da Silva, Ana, Waddington Cruz, Marcia, Planté-Bordeneuve, Violaine, Lozeron, Pierre, Suhr, Ole B., Campistol, Josep M., Conceição, Isabel Maria, Schmidt, Hartmut H.-J., Trigo, Pedro, Kelly, Jeffery W., Labaudinière, Richard, Chan, Jason, Packman, Jeff, Wilson, Amy, Grogan, Donna R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lippincott Williams & Wilkins 2012
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4098875/
https://ncbi.nlm.nih.gov/pubmed/22843282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3182661eb1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller